Company: PFSA
Filing Date: 2025-10-29
Form Type: 424B3
Source: 0001213900-25-103174
Chunk: 82

Company: Profusa, Inc.
Filing Date: 2025-10-29
Form: 424B3
Chunk 82
---
ation of our technology or to prevent an unauthorized third party from copying or otherwise
obtaining and using our products, technology or other information that we regard as proprietary. In addition, third parties may be able
to design around our patents. Furthermore, the laws of foreign countries may not protect our proprietary rights to the same extent as
the laws of the United States.

We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.

Competitors may infringe on
our patents or the patents that we license. In the event of infringement or unauthorized use, we may file one or more infringement lawsuits,
which can be expensive and time-consuming. An adverse result in any such litigation proceedings could put one or more of our patents at
risk of being invalidated, being found to be unenforceable or being interpreted narrowly and could put our patent applications at risk
of not issuing. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation,
there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation.

Many of our competitors are
larger than we are and have substantially greater resources. They are, therefore, likely to be able to sustain the costs of complex patent
litigation longer than we could. In addition, the uncertainties associated with litigation could have a material adverse effect on our
ability to raise any funds necessary to continue our operations, continue our internal research programs, in-license needed technology,
or enter into development partnerships that would help us bring our products to market.

<div align='center'>44</div>

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed alleged trade secrets of their other clients or former employers to us, which could subject us to costly litigation.

As is common in the medical
device industry, we engage the services of consultants and independent contractors to assist us in the development of our products. Many
of these consultants and independent contractors were previously employed at, or may have previously provided or may be currently providing
consulting or other services to, universities or other technology, biotechnology or pharmaceutical companies, including our competitors
or potential competitors. We may become subject to claims that we, a consultant or an independent contractor inadvertently or otherwise
used or disclosed trade secrets or other information proprietary to their former employers or their former or current clients. We may
similarly be subject to claims stemming from similar actions of an employee,